

and upper lips, and, less commonl , on the forearms.² Moreover, melasma is classified as epidermal, dermal, and a combination of the epidermal and dermal t pes according to the depth of melanin pigment in skin.³

Recentl the histopathologic features of melasma investigated and considered that not onl is melasma a melanoc tes disease, but also because of conditions such as solar elastosis, altered basement membrane, increased vasculari ation, and increased mast cell count, it is classified as a photo-aging skin disorder.⁴

This chronic condition can be persistent and ma cause depression, low self-esteem, anxiet , and social phobia in patients. The main risk factors are genetics, pregnanc , sun exposure, contraceptives, and cosmetics.³

Recentl a triple combination formula which contains h droquinone 4%, tretinoin 0.05%, and fluocinoloneacetonide 0.01% (Tri-Luma Cream, Galderma, USA) has been approved b the US FDA and considered as a gold standard for treatment of melasma.⁵

H droquinone (2–5%) is considered the primar and most effective topical agent for blocking melanin production through inhibition of t rosinase e me in melanoc tes.⁶ H droquinone shows low efficac as monotherap , and the disease usuall recurs. T picall , 4–6 weeks are required for a visible response; however, complete treatment of melasma ma take up to 6 months. Higher concentrations of h droquinone might be more effective but with a higher potential for irritation (itching, burning, dermatitis). Therefore, in the combination formula, 4% were used as an optimum concentration with more effectiveness and less adverse reactions.⁷

Tretinoin, another component of the triple combination cream, works b motivating epidermal and dermal turnover, which ma cause rapid loss of cell pigment.⁸ In addition, it inhibits t rosinase e me, facilitates the penetration of h droquinone, and neutrali es the stratum corneum thinning effects of the corticosteroid.⁹

Fluocinolone (a mid-potenc class V steroid) can reduce the possible irritation or inflammation caused b tretinoin and h droquinone, especiall in sensitive skins.¹⁰

Numerous studies of treatment of melisma with triple combination have included patients from North and Latin America and Eastern Asia with dark skins.^{1,11,12} The aim of this stud was to assess the efficac and safet of a topical triple combination of h droquinone, tretinoin, and fluocinolone (Januluma cream produced b Janus Pharmaceutical Co, Tehran, Iran) in the treatment of melasma in Middle Eastern patients.

Patients and methods

This was a phase II, before and after clinical trial, which was conducted in the Center for Research & Training in Skin Diseases & Lepros , Tehran Universit of Medical Sciences from June 2016 to September 2017.

The stud was conducted according to the ethical principles of the Declaration of Helsinki and in compliance with the guidelines of Good Clinical Practice (GCP). The stud protocol was approved b the Ethics committee of Islamic A ad Universit (medical branch) with the acceptance code: IR.IAU.REC.1395.13 in Ma 2016, and registered in the Iranian Registr of Clinical Trials (IRCT) with the registration number of 2016121031288N2.

Women aged 18–50 ears, skin t pe III–IV and a clinical diagnosis of mild-to-severe melasma (Melasma Global Severit Score, MGSS, grade 1 and more) were enrolled, after signing a written informed consent form. The subjects also provided consent for publication of an pictures.

Pregnant women, patients using oral contraceptive pills or immunosuppressive drugs, those with a histor of h pertrophic scars or keloids, or with a recent histor of chronic s stemic disorders, patients who had contraindications for corticosteroid treatment, or an histor of an procedural or topical or oral treatment for melasma within 3 months prior to the stud were excluded. Volunteers were also excluded if the were expected to have an severe exposure to the sun during the stud .

The test product was Januluma cream, produced b Janus Pharmaceutical Co, Tehran, Iran, which contains h droquinone 4%, tretinoin 0.05%, and fluocinoloneacetonide 0.01% in O/W basis.

Participant fulfilling inclusion and exclusion criteria were instructed to wash their skin with mild cleansers and then appl Januluma on melasma lesions ever night, 30 minutes before bedtime, for 8 weeks. The were also instructed to appl moisturi er and broad spectrum sunscreen with SPF 30 or more and a critical wavelength >375 nm regularl all da .

Modified MASI scoring: Before intervention and 4 and 8 weeks later, the intensit and extension of melasma

were assessed based on the Modified Melasma Area and Severity Index (mMASI) scoring method.¹³

The mMASI score was calculated according to the following equation:

$$\text{mMASI total score} = 0.3A_{(f)}D_{(f)} + 0.3A_{(lm)}D_{(lm)} + 0.3A_{(rm)}D_{(rm)} + 0.1A_{(c)}D_{(c)}$$

where A is the area of involvement, D is the darkness of melasma, f is the forehead region, lm is the left malar region, rm is the right malar region, and c is the chin region. The range of the total score is 0–24.

Area and darkness are scored as follows:

Area of involvement : 0 = absent, 1 ≤ 10%,
2 = 10 – 29%, 3 = 30 – 49%,
4 = 50 – 69%, 5 = 70 – 89%,
and 6 = 90 – 100%.

Darkness : 0 = absent, 1 = slight,
2 = mild, 3 = marked,
and 4 = severe

Standardized photographs were taken using a digital camera (Canon Power shot A495) at a fixed position and distance from the participant, and the mMASI score was measured by two independent dermatologists, and the mean was used for assessments.

- **Severity of pigmentation (E value) and skin lightness (L value):** In order to evaluate pigmentation and lightening of lesions, high-resolution frontal images of the face were taken using the VisioFace Quick system (Courage & Kharkia electronic GmbH, Cologne, German) and analyzed using the VisioFace CSI software before intervention, and 4 and 8 weeks after intervention.
- **Biophysical parameters:** Skin melanin index, erythema, pH, sebum, hydration, and TEWL were evaluated before intervention and 4 and 8 weeks after treatment in standardized conditions (temperature and humidity controlled room 20 °C and 30–40%, respectively and after an acclimatization time of 20 minutes) according to in-house SOPs, using a non-invasive multi-probe adapter system MPA580 (Courage & Kharkia electronic GmbH, Cologne, German) respective probes: Mexameter,

pH meter, Sebumeter, Corneometer, and TEWA meter.

- **Ultra-sonography:** High-frequency ultrasound digital apparatus (DUB-USB skin scanner, tpm Co. Luneburg, German) with probe 22 MHz was used to measure the thickness and echodensity of the epidermal and dermal layers.

The participants' satisfaction was measured by VAS (0=no satisfaction and 10=highest satisfaction) in both follow-up visits.

To evaluate the tolerability of the tested cream, the subjects were asked to record any dryness, itching, stinging, redness, desquamation, or ocular intolerance during the treatment. In case of any severe adverse effects, the area was photographed and, if the participant could not continue the study, the use of cream was stopped and the measurements were done on the same or next day.

Statistical analysis was performed using SPSS Software version 20.0 (IBM, USA), and results were presented as the mean standard deviation for quantitative variables. Skin parameters at weeks 4 and 8 were compared with baseline values using paired sample t-test, and the statistical significance was set at P-values less than 0.05.

Results

Twenty-two female patients with mild-to-severe melasma were enrolled, and the background characteristics and demographics are shown in Table 1; 60% of patients had experience of prior treatments for melasma with no satisfactory clearance. Of these cases, 82% were on topical depigmentation creams (cosmetic, pharmaceutical, or compounding preparations).

Seventeen patients (mean age 39.20 ± 4.16 years) completed the study and five discontinued the study in week 4. Two decided to have a baby and three of them said the treatment was not effective.

Figure 1 demonstrates the mean mMASI score, which improved significantly during the study. It decreased from 3.61 ± 0.81 at baseline to 2.81 ± 1.41 at week 4 (P=0.001), and to 2.45 ± 0.81 at week 8 (P<0.001).

Table 1 Demographic and clinical characteristics of subjects

Subject	Number (percentage) of subjects
Pattern of melasma	
	(10 / 22) (%)
	(10 / 22) (%)
	(12 / 22) (%)
Melasma intensity (M G)	
	(10 / 22) (%)
	(10 / 22) (%)
	(12 / 22) (%)
Age (years)	
—	(10 / 22) (%)
—	(10 / 22) (%)
—	(10 / 22) (%)
—	(12 / 22) (%)
Skin type	
	(10 / 22) (%)
	(12 / 22) (%)
Family history	
—	(10 / 22) (%)
—	(12 / 22) (%)
Hormonal disorder	
—	(10 / 22) (%)
—	(10 / 22) (%)
—	(12 / 22) (%)
Duration of melasma (years)	
—	(10 / 22) (%)
—	(12 / 22) (%)
Previous treatment	
—	(10 / 22) (%)
—	(12 / 22) (%)

As Figure 2 shows, 4 and 8 weeks after applying Januluma, skin lightening factor (L value) increased, and this enhancement was significant in week 8 ($P=0.01$).

The average E Value, which reflects the skin pigmentation severity, decreased significantly from baseline (5.34 ± 2.32) after 4 weeks (3.40 ± 2.23), and 8 weeks (3.23 ± 1.89) (P -value=0.001).

The melanin index was monitored by Mexameter after intervention at weeks 4 and 8. The average level of melanin index reduced in both follow-up visits (Figure 3), and this reduction was statistically significant at week 8 ($P=0.001$). The reduction of skin pigmentation and melanin in one of the patients 8 weeks after treatment with Januluma is shown in Figure 4.

TEWL showed a significant increase 8 weeks after treatment with Januluma, while there were no significant changes in other skin biophysical parameters, including hydration, erythema, sebum, and pH (Table 2).

High frequency ultrasonograph evaluation of epidermis and dermis thickness and echo-density did not show any significant changes, except for a significant increase in echo-density of the dermis 8 weeks after treatment (Table 3 and Figure 5).

The mean scores of subject satisfaction rate based on VAS 4 and 8 weeks after treatment were 6.32 ± 1.41 and 6.77 ± 0.96, respectively.

Adverse events including erythema, scaling, and skin dryness were reported in 8, 10, and 14 patients at week 4 and in 7, 8, and 11 patients at week 8, respectively. Most events were mild in intensity and none was severe. The frequency of adverse events reduced from week 4 to week 8. These adverse effects were drug-related and, after finishing the treatment, all side-effects disappeared. No patients discontinued the treatment due to the side-effects.

Discussion

Melasma (also mentioned as chloasma or the pregnancy mask) is a common and benign disorder of facial pigmentation in darker skin prototypes living in areas of intense ultraviolet (UV) radiation, but people of all ages, races, and skin colors may be affected. Presently, melasma treatment remains a challenge, and the search for safe and effective therapies continues.^{7,14}

Despite various pharmaceutical and cosmeceutical ingredients and procedures, combination treatment with once daily application of a mixture of hydroquinone, tretinoin, and fluocinolone acetonide is the only commercial and effective treatment approved by the FDA.^{5,15}

This triple combination has been studied widely in East Asians, Mediterranean Africans, Latino, and Indians ethnics and, proven to be effective in reducing of pigmentation and improving the quality-of-life (QoL) in patients with melasma.^{10,16–21}

As there are no studies in Middle East patients, we assessed a local combination formula (Januluma) on 22 Iranian females with mild-to-severe treatment resistant melasma for 8 weeks.

Triple therapy over 8 weeks reduced MASI scores significantly (Figure 1). This reduction was observed as early as 4 weeks after treatment, and is similar to the previous reports.^{11,22,23} In all of these studies patients used combination therapy for 8 weeks and showed




Figure 1 Line graph showing the change in mMASI over time. The y-axis represents mMASI from 1.5 to 4.0. The x-axis shows Baseline, After 4 weeks, and After 8 weeks. The data points are: Baseline (3.61±0.81), After 4 weeks (2.81±1.41), and After 8 weeks (2.45±0.80). Asterisks indicate significant differences from baseline at 4 and 8 weeks.




Figure 2 Line graph showing changes in skin lightness and skin pigmentation over time. The left y-axis represents Skin lightness from -2.00 to 2.00. The right y-axis represents Skin pigmentation from 0.00 to 6.00. The x-axis shows Baseline, After 4 weeks, and After 8 weeks. Skin lightness (blue line) increases from -1.58±4.32 to -0.31±3.37. Skin pigmentation (orange line) decreases from 5.34±2.30 to 3.23±1.34. Asterisks indicate significant differences from baseline at 4 and 8 weeks for both parameters.

significant reductions ($P < 0.001$) from baseline in MASI at weeks 4 and 8.

Melasma improvement was also accompanied with a significant decrease in skin pigmentation (E value), as shown in in Figure 2. On the other hand, we observed a non-significant increase in skin lightness (L value) and a decrease in melanin index 4 weeks after treatment. These changes might become significant if we had a larger sample size.

This rapid decrease in melanin after 4 weeks is due to hydroquinone, as a tyrosinase inhibitor,²⁴ and also penetration enhancement effect of tretinoin.²⁵ Hydroquinone is

one of the key ingredients for bleaching, and its effect is usually started after 2–3 weeks.²⁶ Tretinoin can also reduce melanin synthesis by inhibition of tyrosinase transcription after 8 weeks of use,²⁷ and this mechanism adds to hydroquinone action.

Another interesting finding was the significant increase in the echodensity of dermis (Table 3 and Figure 5). This improvement during treatment is related to the effect of tretinoin, which induces dermal proteins production. This is the first study using high frequency ultrasonography for evaluation of a triple combination formula, and confirmed previous




Figure 3 Bar chart showing Melanin Index at Baseline, After 4 weeks, and After 8 weeks. The index decreases significantly over time.




Figure 4 (A) Before treatment; (B) After 8 weeks of treatment. The images show a reduction in skin redness and improvement in skin texture.

reports showing that tretinoin might improve the skin density due to the remodeling effect on collagen and elastin fibers, as well as deposition of glycosaminoglycans.^{9,28} It also shows

redistributing effects on melanin content, which leads to improvement of the hyperpigmentation.²⁹

Generally, fluorinated steroids (used in tested formulation) are used to decrease the irritation potential of hydroquinone and tretinoin. They also have bleaching effects.³⁰ The only concern with topical fluorinated corticosteroids is the potential of skin atrophy. However, according to ultrasound results, topical application of Januluma, not only did not cause skin atrophy, but also led to a relative increase in dermal thickness and density, which is probably due to tretinoin (Table 3). Our non-invasive ultrasonic result is consistent with Bhawan et al's³¹ histological analysis in 2009. They evaluated the skin biopsies in patients treated with a mixture of hydroquinone, tretinoin, and fluocinolone acetonide, and no epidermal or dermal atrophy was seen.

After 8 weeks of treatment, TEWL increased significantly, which might be due to the peeling effect of tretinoin. Skin desquamation and xerosis are common side-effects of tretinoin, which correlates with increased TEWL due to damage to the skin barrier function.^{10,11}

No significant changes were found in skin hydration, erythema, sebum, and pH. This correlates with our observation that Januluma was well tolerated. The majority of adverse events were transient and mild, and none of the patients discontinued treatment due to side-effects. The most common related adverse events were skin irritation, scaling, and discomfort, which were all expected from active ingredients.^{10,32}

The fixed triple combination as the first-line treatment for all melasma types was recommended by many academies of dermatologists, and other combinations (such as hydroquinone+peeling ingredients, 20% ascorbic acid+tretinoin and kojic acid+hydroquinone+peeling ingredients) or single agents were applied only for patients who could not tolerate the adverse effects.²⁷

During treatment with the topical triple combination, patients must be instructed to avoid sun exposure, apply a broad-spectrum sunscreen with a sun-protection factor

Table 2 Summary of skin variables and their changes over time during treatment.

Skin variable	Baseline	4 weeks after treatment	8 weeks after treatment	P-value Baseline vs. 4 weeks	P-value Baseline vs. 8 weeks
TEWL (g/h/m ²)	24.18 ± 13.03	30.70 ± 10.87	36.58 ± 17.01	0.087	0.001
Hydration	75.19 ± 16.51	76.54 ± 19.48	80.82 ± 15.50	0.770	0.317
Erythema index	385.87 ± 72.26	398.04 ± 77.70	400.29 ± 67.20	0.292	0.352
Sebum (μg/cm ²)	22.42 ± 28.88	15.76 ± 12.22	8.88 ± 5.45	0.197	0.051
pH	6.93 ± 0.66	6.75 ± 0.67	7.03 ± 0.607	0.417	0.0687

(SPF) of >30, reapply sunscreen every 2 hours, use moisturizers during the day, and wash their face with mild cleansers.³³ This skincare regime can help to reduce all side-effects.

The recurring nature of melasma needs maintaining the efficacy achieved after triple combination treatment. A study conducted by Arellano et al²³ demonstrated the twice-weekly application of triple combination cream for 6 months was more effective with a lower relapse in severe melasma, while the tapering regimen (three times weekly) treated

7. Gupta AK, Gover MD, Nouri K, Ta'lor S. The treatment of melasma: a review of clinical trials. *J Am Acad Dermatol*. 2006;55(6):1048–1065. doi:10.1016/j.jaad.2006.02.009
8. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. *Arch Dermatol*. 1994;130(6):727–733.
9. Rendon M. Utilizing combination therapy to optimize melasma outcomes. *J Drugs Dermatol*. 2004;3(5 Suppl):S27–S34.
10. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. *Cutis*. 2005;75(1):57–62.
11. Chan R, Park K, Lee M, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. *Br J Dermatol*. 2008;159(3):697–703. doi:10.1111/j.1365-2133.2008.08717.x
12. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. *Am J Clin Dermatol*. 2006;7(4):223–230.
13. Pandya AG, Han LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. *J Am Acad Dermatol*. 2011;64(1):78–83. e2. doi:10.1016/j.jaad.2009.10.051
14. Prignano F, Ortonne J-P, Buggiani G, Lotti T. Therapeutic approaches in melasma. *Dermatol Clin*. 2007;25(3):337–342. doi:10.1016/j.det.2007.04.006
15. Malakooti S, Nasrollahi SA, Kashani MN, et al. Formulation of triple cream for treatment of melasma. *Jundishapur J Nat Pharm Prod*. 2019;14(2).
16. Balkrishnan R, Kell A, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: the pigment trial. *J Drugs Dermatol*. 2004;3(4):377–381.
17. Cestari TF, Hexsel D, Viegas M, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. *Br J Dermatol*. 2006;156:13–20. doi:10.1111/j.1365-2133.2006.07591.x
18. Pasricha J, Khaitan BK, Dash S. Pigmentary disorders in India. *Dermatol Clin*. 2007;25(3):343–352. doi:10.1016/j.det.2007.05.004
19. Halder R, Grimes P, McLaurin C, Kress M, Kenne JJ. Incidence of common dermatoses in a predominantly black dermatologic practice. *Cutis*. 1983;32(4):388–390.
20. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. *J Cosmet Dermatol*. 2007;6(1):36–39. doi:10.1111/j.1473-2165.2007.00288.x
21. Siva athorn A. Melasma in orientals. *Clin Drug Investig*. 1995;10(2):34–40. doi:10.2165/00044011-199500102-00006
22. Grimes P, Kell AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. *Cutis*. 2006;77(3):177–184.
23. Arellano I, Cestari T, Ocampo-Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. *J Eur Acad Dermatol Venereol*. 2012;26(5):611–618.
24. Wolverton SE. *Comprehensive Dermatologic Drug Therapy*. Oxford (UK). Elsevier Health Sciences; 2012.
25. Khunger N, Sarkar R, Jain R. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. *Dermatol Surg*. 2004;30(5):756–760. doi:10.1111/j.1524-4725.2004.30212.x
26. Khanna N, Rasool S. Facial melanoses: Indian perspective. *Indian J Dermatol Venereol Leprol*. 2011;77(5):552. doi:10.4103/0378-6323.84046
27. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. *J Am Acad Dermatol*. 2006;54(5):S272–S81. doi:10.1016/j.jaad.2005.12.039
28. Kong R, Cui Y, Fisher GJ, et al. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. *J Cosmet Dermatol*. 2016;15(1):49–57. doi:10.1111/jocd.12193
29. Kang HY, Valerio L, Bahadoran P, Ortonne J-P. The role of topical retinoids in the treatment of pigmentary disorders. *Am J Clin Dermatol*. 2009;10(4):251–260.
30. Kanwar A, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. *Dermatology*. 1994;188(2):170. doi:10.1159/000247129
31. Bhawan J, Grimes P, Pandya AG, et al. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. *Am J Dermatopathol*. 2009;31(8):794